Monoclonal antibodies can induce antibody-dependent cellular cytotoxicity (ADCC) via the innate immune system's ability to recognize mAb coated cancer cells and activate immune effector cells. Lenalidomide is an immunomodulatory agent with the capacity to stimulate immune cell cytokine production and ADCC activity. Cetuximab and lenalidomide were well-tolerated. There was a lenalidomide dose-dependent increase in ADCC with higher activity in patients enrolled in cohort 3 than those enrolled in cohorts 1/2. Although response was not a primary endpoint, there was evidence of anti-tumor activity for the combination therapy. Further investigation of lenalidomide as an immunomodulator in solid tumors is warranted.
INTRODUCTION
Cetuximab is a chimeric IgG1 mAb directed against the extracellular domain of the epidermal growth factor receptor (EGFR). EGFR is a transmembrane protein whose overexpression is associated with a malignant phenotype and the enhanced ability of certain tumors to invade normal tissues and metastasize (8) Lenalidomide is an immunomodulatory agent currently approved for use in hematologic malignancies, but it has shown no significant anti-tumor activity in solid tumors as a single agent (10, 11) . Lenalidomide has demonstrated synergistic activity in combination with several monoclonal antibodies for hematologic malignancies, including rituximab (IgG1 anti-CD20 chimeric mAb) and SGN-40 (IgG1 anti-CD40 humanized mAb) (12) (13) (14) (15) . In vitro studies have shown that lenalidomide stimulates the proliferation and activation of NK cells, thereby enhancing NK cell-mediated cytotoxicity of Ab-coated tumors (16) . Studies in hematologic malignancies (lymphoma and multiple myeloma) also demonstrated a role for the presence of lenalidomide in the activation of natural killer (NK) cells (CD16 + CD56 low ) (14, 17) . These findings support the role of lenalidomide in enhancing immune cell-mediated cytotoxicity (14, 17, 18) . Preclinical studies of lenalidomide in SCID lymphoma mice also demonstrated enhancement of ADCC due to NK cell activity and increased cytokine activity (14, 18) .
The present phase I clinical trial evaluated the safety, toxicity and immunologic activity of the combination of lenalidomide and cetuximab in patients with colorectal and head and neck squamous cell cancer. Based on pre-clinical and clinical work with lenalidomide and mAbs, one of the primary aims was to evaluate the role of NK cell-mediated ADCC of cetuximab using lenalidomide as an immune stimulant. 
MATERIALS AND METHODS

Patient selection.
Patients with metastatic KRAS wild-type colorectal cancer (CRC) or squamous cell head and neck cancer were eligible to enroll (HNSCC). All patients provided written informed consent. There was no limit to the prior number of therapies that could be received. Prior EGFR-directed therapy (e.g. tyrosine kinase inhibitors and monoclonal antibodies) including cetuximab, panitumumab, or investigational EGFR directed monoclonal antibodies was allowed. No chemotherapy or monoclonal antibody therapy was permitted within 28 days of trial initiation. Additional eligibility criteria included ECOG performance status 0-2, negative pregnancy test and use of contraception in women of child-bearing age and preserved organ function as defined by the following parameters: leukocytes >3,000/mcL, absolute neutrophil count >1,500/mcL, platelets >100,000/mcL, total bilirubin < 1.5 mg/dL, AST (SGOT) < 100 U/L, ALT (SGPT) < 120 U/L, creatinine clearance > 60 mL/min/1.73 m 2 as calculated using modified Cockcroft-Gault formula. Patients with brain metastases who had received definitive therapy, including radiation, and did not require ongoing medical therapy (i.e. steroids) for brain metastases were eligible. Exclusion criteria included history of allergic reactions attributed to compounds with chemical or biologic composition similar to lenalidomide or cetuximab, DVT/PE requiring therapy within 3 months of enrollment, history of toxicity ≥ grade 3 with prior EGFR-directed therapy, confirmed history of interstitial lung disease, uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant woman and patients less than 18 years of age were excluded. Due to the use of a commercial supply of cetuximab, KRAS mutant CRC was specifically excluded in accordance with FDA indication for this drug. provider at the start of each treatment cycle. Patients were assessed for response with CT imaging every 2 cycles (8 weeks). Treatment was continued until unacceptable toxicity, disease progression, patient withdrawal from study or investigator discretion. Patients were followed for 6 weeks after removal from study or until death, whichever occurred first. Patients removed from the study for unacceptable adverse events were followed until resolution or stabilization of the adverse event.
Correlative studies. Peripheral blood samples were obtained at study entry and after initiation of lenalidomide therapy at days 15, 30, and 45. Combination therapy (cetuximab and lenalidomide) was continued beyond day 45 unless patients were removed from the study due to intolerance or toxicity. Serum and peripheral blood mononuclear cells (PBMCs) were procured and cryopreserved using standard techniques and used for further analysis (19) .
Antibody-dependent cellular cytotoxicity:
PBMCs from patients at various time points were plated in 96-well V-bottom plates and treated with or without IL-12 (10 ng/ml) overnight in RPMI supplemented with 10% human AB serum at 37°C. Eighteen hours later, HT29 human colorectal cancer tumor cells were labeled with 51 Cr for 1 hour, followed by incubation with either cetuximab or control IgG (50 ug/ml) for 45 minutes. Tumor cells were then added to NK cells at various effector: target (E:T) ratios. Following 4 hour incubation, supernatants were harvested and chromium release was assayed and percent lysis determined as previously described (20) . The human colorectal cancer cell line HT29 was acquired from ATCC in 2010 and was validated by karyotyping/cytogenetic analysis prior to use in 2013.
FcγRIIIA genotyping: DNA was isolated from pretreatment patient PBMCs using a QIAmp kit according to the manufacturer's instructions (Qiagen, Valencia, CA) and quantified. Genotyping of the FcγRIIIA-158V/F polymorphism was performed using a nested PCR followed by allele-specific restriction enzyme digestion as 
RESULTS
Patient characteristics. Twenty-two patients (6 women, 16 men) were enrolled. Nineteen patients had colorectal cancer (KRAS wild-type) and 3 patients had squamous cell carcinoma of the head and neck. The average patient age was 61 years old (range 44 -71 years); most patients were Caucasian (20 Caucasian, 2 African-American). All but one patient had received prior EGFR directed therapy: 11 patients had received cetuximab, 6 patients had received panitumumab, and 4 patients received both cetuximab and panitumumab.
The patients were heavily pre-treated -most patients received at least 4 prior regimens in the metastatic setting Table 1 . events were reported at dose levels 2 and 3. None of these events proceeded to pulmonary embolus and were managed with anti-coagulation only. No patients required dose reductions. No treatment related grade 5 toxicity was observed. Toxicities are further detailed in Table 2 .
Anti-tumor activity. Evaluable patients received an average of 4 treatment cycles. One patient had a partial response to treatment that began with cycle 2. They received a total of 8 cycles of therapy prior to progression of disease. Eight patients had stable disease as their best response; 10 patients had progressive disease after 2 cycles. Patients with stable disease received an average of 6 cycles of therapy (range 4-10 cycles). All but one of the patients with clinical benefit (partial response or stable disease) had received prior EGFR-directed therapy. Patient characteristics and response evaluation detailed in Table 3 .
Correlative studies. Due to small patient numbers, cohorts 1 and 2 were combined and compared to cohort 3 for statistical analysis. In cohort 1 and 2, the mean change in ADCC between day 45 post treatment and baseline samples was -2.45% (95%CI: -7.18, 2.27, p=0.305), indicating no significant increase in ADCC activity. In cohort 3, the mean change in ADCC between day 45 post treatment and baseline samples was 7.53% (95%CI: 1.65, 13.4, p=0.0125), which is significantly greater than that in the combined cohorts 1 and 2 (p=0.01) (Figure 1 ). Likewise, there was a trend towards increased ADCC activity in patients with clinical benefit (those patients with either stable disease or response) compared to patients who did not experience clinical benefit. For patients who experienced clinical benefit, the mean change in ADCC at day 45 (compared to baseline) was 6.87% (95% CI: -0.22 -13.97, p= 0.0573); in patients with progression after 2 cycles, the mean difference at day 45 (compared to baseline) was 2.69% (95% CI: -3.74 -9.63, p = 0.4210) (Figure 2 ). No high affinity Fc gamma receptor polymorphisms (VV) were identified. The group was evenly split with 11 VF and 11 FF polymorphisms identified (dns). There was no significant association between polymorphism status and clinical benefit, toxicity, or ADCC activity. In addition, levels of IL-2, IL-12, IFN-γ, TNF-α, VEGF, and FGF-basic were measured in serum drawn at baseline and days 15, 30, and 45, however no significant differences in serum cytokine levels were seen in patients with clinical benefit compared to patients who did not experience clinical benefit (Figure S1A-B) . The percentage of T regulatory cells, T cells, NK cells, and monocytes was determined by flow cytometry for 10 patients enrolled in cohort 3, however, no significant differences in any of these populations were noted or indicative of patient outcome ( Figure S2A-D) .
DISCUSSION
This phase I trial of cetuximab and lenalidomide demonstrated that the combination was well-tolerated and no excessive toxicities were observed. The observed toxicities were within the expected range for these agents, with the exception of the increased risk of thromboembolic disease (27% in this trial). Based on clinical tolerability, the recommended phase II dose for further evaluation of this combination is cetuximab 500 mg/m 2 IV days 1 and 14 with lenalidomide being dosed at 25 mg on days 1-21 of 28 day cycle.
Thromboembolism is a known risk of lenalidomide therapy. Initial trials leading to drug approval in the United State reported thrombosis in up to 10% of multiple myeloma patients treated with lenalidomide and dexamethasone (6, 7) . Studies of lenalidomide in solid tumors demonstrated a variable rate of venous thromboembolism: thyroid cancer (11% pulmonary embolism) (23), pancreatic cancer (18%) (23), and phase I study of multiple cancer types (13%) (10) . It is also noted that solid tumor patients have an increased risk of thromboembolic disease compared to the general population. In particular, gastrointestinal tumors carry one of the highest risks of this complication (odds ratio 16.8 (4.1 -69.1) (24) . In this context, the increased risk of venous thrombosis suggests that a more aggressive prophylaxis regimen may be indicated for this population of patients if lenalidomide is utilized with cetuximab.
The observed response rate of combination therapy suggests lenalidomide may play a role in improving single agent activity of cetuximab, particularly in pre-treated patients. Cetuximab was initially approved as a single agent therapy in CRC based on a phase III trial demonstrating a partial response rate of 8% and stable disease in 31% of patients (25) . When only KRAS wild-type patients were included, the response rate was 12.8% (26) .
Similarly, a non-inferiority trial of cetuximab versus panitumumab demonstrated a response rate of 20-22% with stable disease in 47-49% of patients without prior exposure to EGFR inhibitors (27) . Likewise, 
single-agent cetuximab demonstrated response rate of 13% in recurrent/metastatic squamous cell head and neck cancer (28) . The potential benefit of re-challenging patients with single-agent EGFR directed therapy after prior exposure is less clear. One published trial evaluated the efficacy of using panitumumab in patients who had progressed on cetuximab, and a small phase II trial observed no responses, but 45% of patients had stable disease for at least 2 cycles (29) . A second small study reported a clinical benefit rate of 15% in patients with cetuximab-resistance (30) . Thus the use of immunostimulatory agents including lenalidomide may have the greatest benefit in patients who have had prior EGFR-directed therapies.
Although clinical benefit/response rate was not a primary endpoint in this trial, we did observe clinical benefit in 9 patients (47% of patients completing at least 2 cycles) with one partial response. The patient with a partial response had been previously treated with panitumumab in combination with irinotecan as well as cetuximab. benefit. These endpoints are exploratory but suggest that immunologic activity may underly the benefit for individual patients.
Cetuximab plus lenalidomide is a well-tolerated combination therapy. Clinical benefit was observed with tolerable toxicity. In addition, immune activity was observed and improved with increasing doses of lenalidomide. Given the limited activity observed in this small patient population, it would be interesting to explore the use of lenalidomide with other EGFR-directed therapies. 
